DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R ... agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive ...

The PRAC still has another safety review on the go for the GLP-1 class ... by Ozempic and Mounjaro (tirzepatide), Lilly’s dual GLP-1/GIP agonist.

DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist ... 119 (GPR119) agonist that promotes the ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Discover the effectiveness and safety of Mounjaro, the new weight loss drug launched in India. Learn from expert Dr. Pal ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: ...